ER and PR
Hormone receptors absent
Endocrine therapy is not expected to treat a tumor that truly lacks hormone receptors.
Breast Cancer Subtype · TNBC
Triple-Negative Breast Cancer Treatment With an Integrative Strategy
Triple-negative breast cancer lacks ER, PR and HER2 targets. Treatment planning therefore depends heavily on stage, chemotherapy response, PD-L1, inherited mutations, recurrence pattern and emerging targets.
Answer first: TNBC treatment may include chemotherapy, immunotherapy, surgery, radiation, targeted therapy for selected mutations and clinical trials. A broader integrative program can support strength, symptoms, immune health and recovery.
Cancer Consultation
Speak With Our Cancer Patient Care Team
Tell us where you are in your cancer journey. Our Patient Care Team can answer questions and help determine the next step.
*
Required fields
Prefer to speak with someone now?
1-800-923-7878
✓
Stage 4 & advanced cancer patients welcome
✓
Out-of-state & international patients welcome
✓
Questions before scheduling are welcome
What triple-negative means
Three absent targets—but not an absence of treatment options.
HER2
No HER2 overexpression
Classic HER2-directed therapy is not used for HER2-negative disease, although HER2-low status may create a different option later.
More testing
Look beyond the three negatives
PD-L1, BRCA1/2, PALB2, HER2-low expression and other biomarkers can influence choices.
TNBC treatment protocols
Examples across early and metastatic disease.
Early and locally advanced TNBC
Neoadjuvant regimens may include paclitaxel (Taxol), carboplatin (Paraplatin), doxorubicin (Adriamycin) and cyclophosphamide (Cytoxan). Pembrolizumab (Keytruda) may be combined with chemotherapy in defined high-risk settings.
After surgery
Pathologic response helps guide the next step. Additional pembrolizumab, capecitabine (Xeloda) or olaparib (Lynparza) may be considered in defined situations.
Metastatic TNBC
Chemotherapy, pembrolizumab for eligible PD-L1-positive disease, PARP inhibitors for eligible inherited mutations, sacituzumab govitecan (Trodelvy), other antibody-drug conjugates and clinical trials may be considered.
Testing that matters in TNBC
A negative label should trigger a positive search for actionable information.
- Confirm pathology and receptor testing quality.
- Obtain germline hereditary-cancer testing when indicated.
- Evaluate PD-L1 using the assay and scoring system relevant to the treatment question.
- Review HER2 IHC details rather than only the word “negative.”
- Consider tumor genomic profiling or liquid biopsy in recurrent or metastatic disease.
Integrative TNBC support
An active plan for resilience and recovery.
Immune context
NK cells, lymphocytes and inflammation
Selected immune measurements may contribute context while standard pathology and response assessment remain central.
Supportive care
Coordinated care planning
Supportive options are evaluated according to symptoms, laboratory findings, medications and the complete oncology treatment schedule.
Interaction review
Nutritional and botanical review
These approaches are considered according to evidence, safety, dose, treatment goals and potential interactions with cancer therapy.
Emerging support
Hydrogen inhalation
Molecular hydrogen is an emerging modality with early human oncology research outside breast cancer and active interest in supportive applications .
Questions patients ask
TNBC FAQs
Is TNBC always Stage 4?
No. TNBC can be diagnosed at Stage I, II, III or IV.
Can TNBC have a hereditary cause?
Some TNBC is associated with inherited BRCA1, BRCA2 or other variants, which can affect family counseling and treatment.
What records should I send for a review?
Send pathology, receptor and PD-L1 reports, genetic results, imaging, treatment history, recent laboratory results and a current medication list.
A closer look
How this topic fits the complete breast-cancer plan.
TNBC decisions can change rapidly because response to preoperative therapy provides important information. The pathology report after surgery should state whether a pathologic complete response was achieved and, when residual disease remains, describe its extent. In metastatic TNBC, the site and speed of progression, PD-L1 result, inherited genetics, HER2-low expression and previous chemotherapy exposure help organize the next choices.
An integrative TNBC program should be equally specific. The patient’s blood counts, neuropathy, gastrointestinal function, sleep, muscle loss, inflammatory burden and recovery between cycles can guide supportive priorities. Sunridge may combine nutrition, movement, infusion support, natural compounds, immune-context testing and emerging modalities within a physician-directed plan that is reassessed as treatment and disease status change.
Prepare for a Sunridge review
The right records make the first conversation more useful.
Before contacting the Patient Care Team, gather pathology, PD-L1 assay details, hereditary testing, surgical pathology, imaging, treatment response and current laboratory results. A concise one-page chronology is often helpful: diagnosis date, stage, major test results, treatments received, response, side effects and the questions that matter most now.
Step 1
Send the records
The team can explain which reports and images are needed before a physician review.
Step 2
Define the priorities
List the treatment, symptom, recovery and quality-of-life questions you want the consultation to address.
Step 3
Plan the visit
Out-of-state and international patients can discuss timing, Scottsdale travel and which services require an in-person appointment.
A personalized next step
Bring the complete breast-cancer story to the conversation.
Our Patient Care Team can explain which records to send, how a physician review works and what to expect when traveling to Scottsdale.
Request a consultationCall 1 -800-923-7878This page is educational and does not provide a diagnosis or individualized treatment recommendation. Medication and integrative-treatment decisions require review of the complete case by qualified clinicians. Content reviewed August 2026 .